Tirzepatide
SURMOUNT-OSA
Eli Lilly · Phase 3 · Completed · Enrollment 469
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide MTD_GPI1 | 29 participants | 20 participants | 30 participants | n/r | 0 |
| Placebo_GPI1 | 12 participants | 5 participants | 15 participants | n/r | 0 |
| Tirzepatide MTD_GPI2 | 26 participants | 11 participants | 26 participants | n/r | 0 |
| Placebo_GPI2 | 6 participants | 1 participants | 10 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.